VERA_Thumbnail.jpg
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
29 oct. 2024 20h21 HE | Vera Therapeutics
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
28 oct. 2024 17h37 HE | Vera Therapeutics
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Figure 1.
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
26 oct. 2024 19h30 HE | Vera Therapeutics
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the...
VERA_Thumbnail.jpg
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2024 16h05 HE | Vera Therapeutics
BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
02 oct. 2024 06h30 HE | Vera Therapeutics
PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
02 oct. 2024 06h30 HE | Vera Therapeutics
Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney Week;In-person and virtual R&D Day to discuss expanded atacicept...
VERA_Thumbnail.jpg
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
16 sept. 2024 08h00 HE | Vera Therapeutics
BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
12 sept. 2024 08h00 HE | Vera Therapeutics
On track to announce topline results from ORIGIN 3 trial in Q2 2025Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024 BRISBANE, Calif., Sept. 12,...
VERA_Thumbnail.jpg
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 sept. 2024 16h05 HE | Vera Therapeutics
BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards consisting...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate at September Investor Conferences
29 août 2024 08h00 HE | Vera Therapeutics
BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...